SG/PUT/NOVO-NORDISK B/1000/0.1/21.03.25 | Market Closed - Bid/Ask 20:19:11 03/07/2024 BST | ||
| 1.74 EUR | +12.26% |
|
| Current month | +13.07% | ||
| 1 month | -13.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 1.74 | +12.26% |
| 02/07/24 | 1.55 | +7.64% |
| 01/07/24 | 1.44 | -5.88% |
| 28/06/24 | 1.53 | +2.00% |
| 27/06/24 | 1.5 | +0.67% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 08:19 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7ZJP |
| ISIN | DE000SW7ZJP2 |
| Date issued | 20/03/2024 |
| Strike | 1,000 kr |
| Maturity | 21/03/2025 (261 Days) |
| Parity | 10 : 1 |
| Emission price | 2.46 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.92 € |
|---|---|
| Lowest since issue | 1.36 € |
| Spread | 0.06 € |
| Spread % | 3.33% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Warrants
- Warrant
